

PARTICULARS TO APPEAR ON THE OUTER PACKAGE {Outer cardboard box}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Dormazolam 5 mg/ml solution for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:
Midazolam 5.0 mg

3. PACKAGE SIZE

5 ml
10 ml
20 ml
50 ml

4. TARGET SPECIES

Horse (non food-producing)



5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Intravenous use.

7. WITHDRAWAL PERIODS

Not authorised for use in horses intended for human consumption.

8. EXPIRY DATE

Exp. {mm/yyyy}

Once broached use within 28 days
Once broached use by:

9. SPECIAL STORAGE PRECAUTIONS

Keep the vial in the outer carton in order to protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Dechra Regulatory B.V.

14. MARKETING AUTHORISATION NUMBERS

Vm 50406/5009

Vm 50406/3006

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS {Glass vials of 5, 10, 20 or 50 ml}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Dormazolam



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Midazolam 5 mg/ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once broached use within 28 days.
Once broached, use by:

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Dormazolam 5 mg/ml solution for injection for horses

2. Composition

Each ml contains:

Active substance:

Midazolam 5.0 mg

Excipient(s):

Benzyl alcohol (E1519) 10.0 mg

Clear, colourless solution.

3. Target species

Horse (non food-producing).

4. Indications for use

Co-induction of anaesthesia with ketamine for smooth induction and intubation and profound muscle relaxation during anaesthesia.

5. Contraindications

Do not use in animals with severe respiratory failure.

Do not use as a sole agent in horses.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. Special warnings

Special precautions for safe use in the target species:

In case of renal or hepatic dysfunction or respiratory depression there may be greater risk associated with the use of the veterinary medicinal product. Use only according to the benefit/risk assessment by the responsible veterinarian.

The veterinary medicinal product is not intended for sole use; Midazolam produces muscle relaxation; when used as a sole agent horses may be slightly sedated, but also restless or even agitated when they become ataxic/unstable.

Prolonged recovery time (prolonged recumbence and time to extubation) may be

associated with use of the veterinary medicinal product.

The safety of repeated bolus dosing (at 0.06 mg/kg) at intervals of less than 4 days has not been established. Based on the pharmacokinetics of the active substance, care should be taken when administering repeated doses of midazolam within a 24-hour period to horses, particularly neonatal foals (i.e. foals less than 3 weeks old), obese horses and horses with hepatic impairment or conditions associated with reduced organ perfusion, due to the possibility of drug accumulation.

Care should be taken when administering the veterinary medicinal product to hypoalbuminaemic horses since these animals may have higher sensitivity to a given dose.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Midazolam is a CNS depressant and can cause sedation and induction of sleep.

Care should be taken

to avoid self-injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet to the physician, but DO NOT DRIVE as sedation and impaired muscular function may occur.

Midazolam and its metabolites may be harmful for the unborn child, and are secreted into breastmilk in small amounts, thereby exerting a pharmacological effect on the nursing child. Pregnant and breastfeeding women should, therefore, take great care when handling this veterinary medicinal product and, in the event of exposure, seek medical advice immediately.

Midazolam and benzyl alcohol may cause hypersensitivity reactions. People with known hypersensitivity to these substances should avoid contact with the product.

Seek medical advice in case of hypersensitivity reactions.

This product can cause skin and/or eye irritation.

Avoid contact with skin and eyes. In the case of contact with skin, wash with soap and water. If the veterinary medicinal product comes into contact with the eyes, rinse the eyes immediately with plenty of water. If irritation persists, seek medical advice. Wash hands after use.

Advice to physicians: Like other benzodiazepines, midazolam commonly causes drowsiness, ataxia, dysarthria anterograde amnesia, and nystagmus. Overdose of midazolam is seldom life-threatening if the drug is taken alone, but may lead to areflexia, apnoea, hypotension, cardiorespiratory depression and in rare cases to coma.

Monitor the patient's vital signs and institute supportive measures as indicated by the patient's clinical state. Respiratory and haemodynamic symptoms should be treated symptomatically.

Pregnancy and lactation:

Use only according to the benefit/risk assessment by the responsible veterinarian.

Laboratory studies in mice, rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects. In humans, use of benzodiazepines during the late third trimester of pregnancy or during labour has been associated with adverse effects in the foetus/neonate, including mild sedation, hypotonia, reluctance to suck, apnoea, cyanosis and impaired metabolic response to cold stress.

Midazolam is found in low quantities in the milk of lactating animals.

The safety of the veterinary medicinal product during pregnancy and lactation has not been established in the target species. Use only according to the benefit/risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

Before using combinations of midazolam with other veterinary medicinal products, the product literature for the other products should be observed.

Midazolam potentiates the effect of some sedative and anaesthetic agents, reducing the dose required, including alpha-2-agonists (detomidine, xylazine), propofol and some inhalational agents.

Concurrent use of midazolam with antihistamines (H₂-receptor antagonists, e.g. cimetidine), barbiturates, local anaesthetics, opioid analgesics or CNS depressants may enhance the sedative effect.

In combination with other agents (e.g. opioid analgesics, inhalational anaesthetics), an increase in respiratory depression may be observed.

Erythromycin and azole antifungals (fluconazole, ketoconazole) inhibit the metabolism of midazolam, resulting in increased plasma midazolam concentrations and increased sedation.

Drugs that induce CYP450 mediated metabolism, such as rifampin, may decrease plasma concentrations and effects of midazolam.

Overdose:

The symptoms of overdose are mainly an intensification of the pharmacological effects of midazolam: drowsiness, and muscle relaxation.

In case of accidental midazolam overdose, restlessness or agitation in combination with prolonged muscle weakness may develop when the ketamine effect of the combined midazolam-ketamine anaesthesia subsides.

Following a dose of 0.18 mg midazolam per kg bodyweight (3 times overdose) in combination with ketamine (2.2 mg/kg intravenously) after premedication with detomidine (20 µg/kg intravenously) the following effects attributable to midazolam were observed: poor recovery (more attempts to stand, more ataxia), a slight decrease of the haematocrit, respiratory depression - evidenced by a slight decrease of the respiratory rate, a lower pO₂, a metabolic alkalosis and a slight increase of arterial pH - and a prolonged recovery. A dose of 0.3 mg midazolam per kg bodyweight (5 times overdose) using the same combination resulted in a violent recovery, i.e. horse trying to stand up, whilst still having profound muscle weakness.

The benzodiazepine antagonist flumazenil can be used to reverse effects associated with an overdose of midazolam, although clinical experience in horses is limited.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products, except for ketamine 100mg/ml solution for injection.

7. Adverse events

Target species: Horse (non food-producing)

Common (1 to 10 animals / 100 animals treated):	Ataxia ^a , incoordination ^a .
Uncommon (1 to 10 animals / 1,000 animals treated):	Respiratory depression ^b , urination. ^b

^aduring recovery from anaesthesia

^bupon induction of anaesthesia

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

For intravenous use.

Once the horse is properly sedated, anaesthesia is induced by intravenous injection of:

Midazolam at a dose of 0.06 mg per kg body weight, corresponding to 1.2 ml solution per 100 kg, in combination with ketamine at a dose of 2.2 mg per kg body weight. To ensure a correct dosage, body weight should be determined as accurately as possible.

9. Advice on correct administration

Midazolam and ketamine may be combined and administered in the same syringe.

10. Withdrawal periods

Not authorised for use in horses intended for human consumption.

11. Special storage precautions

Keep out of the sight and reach of children.

Keep the vial in the outer carton in order to protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.

Shelf life after first opening the container: 28 days

This veterinary medicinal product does not require any special temperature storage conditions.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 50406/5009

Vm 50406/3006

Packaging:

Colourless Type I glass vials of 5 ml, 10 ml, 20 ml and 50 ml closed with a coated bromobutyl rubber stopper and aluminium cap in a carton box.

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder:

Dechra Regulatory B.V.
Handelsweg 25
5531 AE Bladel
The Netherlands

Manufacturer responsible for batch release:

Produlab Pharma B.V.
Forellenweg 16
4941 SJ Raamsdonksveer
The Netherlands

Local representatives and contact details to report suspected adverse reactions:

Dechra Veterinary Products Limited
Sansaw Business Park
Hadnall
Shrewsbury
Shropshire
SY4 4AS
United Kingdom
Tel: +44 (0) 1939 211200

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

POM-V

Gavin Hall

Approved 19 January 2025